NASDAQ: XERS
Xeris Biopharma Holdings Inc Stock

$16.99+0.19 (+1.13%)
Updated Nov 18, 2026
XERS Price
$16.99
Fair Value Price
N/A
Market Cap
$3.10B
52 Week Low
$5.25
52 Week High
$17.28
P/E
-424.75x
P/B
63.63x
P/S
4.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$368.26M
Earnings
-$6.50M
Gross Margin
87.4%
Operating Margin
5.69%
Profit Margin
-1.8%
Debt to Equity
7.68
Operating Cash Flow
$74M
Beta
1.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

XERS Overview

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine XERS's potential to beat the market

AStrong Buy
  • Stocks with a Zen Rating of Strong Buy (A) had an average return of +28.50% per year. Learn More

Zen Rating Component Grades

B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
XERS
Ranked
#2 of 449

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important XERS news, forecast changes, insider trades & much more!

XERS News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XERS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XERS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XERS is poor value based on its book value relative to its share price (63.63x), compared to the US Biotechnology industry average (4.91x)
P/B vs Industry Valuation
XERS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XERS due diligence checks available for Premium users.

Valuation

XERS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-424.75x
Industry
17.98x
Market
41.36x

XERS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
63.63x
Industry
4.91x
XERS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

XERS's financial health

Profit margin

Revenue
$107.2M
Net Income
$11.3M
Profit Margin
10.5%
XERS's Earnings (EBIT) of $20.94M... subscribe to Premium to read more.
Interest Coverage Financials
XERS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$423.2M
Liabilities
$374.4M
Debt to equity
7.68
XERS's short-term assets ($289.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XERS's short-term assets ($289.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XERS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XERS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$35.5M
Investing
-$159.0k
Financing
-$26.0M
XERS's operating cash flow ($73.65M)... subscribe to Premium to read more.
Debt Coverage Financials

XERS vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
XERSA$3.10B+1.13%-424.75x63.63x
ACADC$3.08B-2.67%8.37x2.22x
LEGNB$3.15B+0.87%-812.50x2.48x
TLX–$3.04B+1.19%N/A8.77x
ADMAC$3.01B-0.51%17.16x6.86x

Xeris Biopharma Holdings Stock FAQ

What is Xeris Biopharma Holdings's quote symbol?

(NASDAQ: XERS) Xeris Biopharma Holdings trades on the NASDAQ under the ticker symbol XERS. Xeris Biopharma Holdings stock quotes can also be displayed as NASDAQ: XERS.

If you're new to stock investing, here's how to buy Xeris Biopharma Holdings stock.

What is the 52 week high and low for Xeris Biopharma Holdings (NASDAQ: XERS)?

(NASDAQ: XERS) Xeris Biopharma Holdings's 52-week high was $17.28, and its 52-week low was $5.25. It is currently -1.68% from its 52-week high and 223.62% from its 52-week low.

How much is Xeris Biopharma Holdings stock worth today?

(NASDAQ: XERS) Xeris Biopharma Holdings currently has 182,700,038 outstanding shares. With Xeris Biopharma Holdings stock trading at $16.99 per share, the total value of Xeris Biopharma Holdings stock (market capitalization) is $3.10B.

Xeris Biopharma Holdings stock was originally listed at a price of $20.22 in Jun 21, 2018. If you had invested in Xeris Biopharma Holdings stock at $20.22, your return over the last 8 years would have been -15.97%, for an annualized return of -2.15% (not including any dividends or dividend reinvestments).

How much is Xeris Biopharma Holdings's stock price per share?

(NASDAQ: XERS) Xeris Biopharma Holdings stock price per share is $16.99 today (as of Nov 18, 2026).

What is Xeris Biopharma Holdings's Market Cap?

(NASDAQ: XERS) Xeris Biopharma Holdings's market cap is $3.10B, as of Nov 20, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Xeris Biopharma Holdings's market cap is calculated by multiplying XERS's current stock price of $16.99 by XERS's total outstanding shares of 182,700,038.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.